Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3Breast Neoplasms 3Brain Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Carcinoma, Squamous Cell 2Carcinoma, Large Cell 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Tonsillar Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × motexafin gadolinium × Clear all
NCT00365183 2013-10-31

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Pharmacyclics LLC.

Phase 2 Terminated
74 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡